The Bombay Burmah Trading Corporation (501425) Q4 98/99 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 98/99 earnings summary
22 Oct, 2026Executive summary
FY99 PAT fell to Rs 7.86 lakh from Rs 808.86 lakh; pre-depreciation gross profit declined to Rs 866.46 lakh from Rs 1,898.62 lakh.
A prolonged Singampatti labor disruption and losses at the newly commissioned particle-board operation were major profit pressures; recession also hurt building products and springs.
Financial highlights
Total income was Rs 14,338.73 lakh versus Rs 14,039.60 lakh; profit before tax was Rs 274.86 lakh versus Rs 1,070.86 lakh.
Revenue from sales was Rs 12,790.98 lakh versus Rs 13,083.41 lakh; interest expense rose to Rs 1,192.69 lakh from Rs 958.19 lakh.
Proposed dividend was 10% (Rs 1 per share), compared with 26% in FY98.
Outlook and guidance
Singampatti was expected to return to normal tea production by September 1999 after bush pruning and weed removal; near-normal conditions had returned in May.
Springs performance was expected to improve with new products and a likely auto-industry recovery; Afcoset Balances outlook was favorable.
Particle Board operations were under a monitored improvement and cost-reduction plan to stabilize output and reduce losses.
Latest events from The Bombay Burmah Trading Corporation
- Higher profit, softer sales and negative operating cash flow defined FY 1996-97.501425
Q4 96/97 - Profit rose on stronger plantation realisations; new manufacturing lines launched.501425
Q4 97/98 - Labour disruption, cost inflation and tea-price pressure drove a sharp loss.501425
Q4 99/00 - Commodity-price pressure and estate disruptions drove another loss; the dividend was skipped.501425
Q4 01/02 - Profit returned as operational gains offset weak tea and coffee markets.501425
Q4 02/03 - Profit rebounded as lower financing costs and industrial gains offset plantation pressures.501425
Q4 03/04 - Higher profits and associate earnings met drought, cost and currency pressures.501425
Q4 04/05 - FY06 profit rose amid cost pressure, with expansion and healthcare poised to drive growth.501425
Q4 05/06 - Standalone earnings improved; acquisitions and new capacity set up growth, with VRS costs deferred to FY08.501425
Q4 06/07